Korea Evaluation Institute of Industrial Technology   Report issue

Government Phase 2
Founded: Seoul Korea, Republic of (2009)

Organization Overview

First Clinical Trial
2019
NCT04013646
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Korea Evaluation Institute of Industrial Technology

Active Ingredients

Drugs in Phase 2 Trials (2)

epoetin (Epogen) (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2